v3.25.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Research and development $ 10,029 $ 9,151 $ 19,310 $ 17,929
General and administrative 6,769 4,205 13,885 11,728
Total operating expenses 16,798 13,356 33,195 29,657
Loss from operations (16,798) (13,356) (33,195) (29,657)
Other income:        
Interest income 270 236 664 568
Other income 209 6 387 6
Total other income 2,065 2,153 4,350 6,343
Net loss (14,733) (11,203) (28,845) (23,314)
Comprehensive loss (14,733) (11,203) (28,845) (23,314)
Net loss, basic (14,733) (11,203) (28,845) (23,314)
Net loss, diluted $ (14,733) $ (11,203) $ (28,845) $ (23,314)
Net loss per share, basic (in dollars per share) $ (0.56) $ (2.45) $ (1.59) $ (5.10)
Net loss per share, diluted (in dollars per share) $ (0.56) $ (2.45) $ (1.59) $ (5.10)
Weighted-average number of shares used in computing net loss per share, basic (in shares) 26,081,273 4,572,010 18,091,478 4,571,377
Weighted-average number of shares used in computing net loss per share, diluted (in shares) 26,081,273 4,572,010 18,091,478 4,571,377
Related Party        
Operating expenses:        
Research and development $ 3,586 $ 3,637 $ 7,656 $ 7,269
Other income:        
GeneFab sublease income - related party 1,586 1,587 3,299 3,047
Change in fair value of GeneFab Option - related party        
Other income:        
Change in fair value 0 1,631 0 3,945
Change in fair value of GeneFab Economic Share - related party        
Other income:        
Change in fair value 0 (1,473) 0 (1,418)
Change in fair value of GeneFab Note Receivable - related party        
Other income:        
Change in fair value $ 0 $ 166 $ 0 $ 195